A Phase II Study of SU011248 in patients with metastatic mucosal or acral/lentiginous melanoma.
Phase of Trial: Phase II
Latest Information Update: 13 Dec 2016
At a glance
- Drugs Sunitinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 16 Oct 2016 Status changed from active, no longer recruiting to completed.
- 08 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016.
- 19 Jan 2016 Planned End Date changed from 1 Feb 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.